These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 38699313)

  • 61. AlphaFold2 Modeling and Molecular Dynamics Simulations of the Conformational Ensembles for the SARS-CoV-2 Spike Omicron JN.1, KP.2 and KP.3 Variants: Mutational Profiling of Binding Energetics Reveals Epistatic Drivers of the ACE2 Affinity and Escape Hotspots of Antibody Resistance.
    Raisinghani N; Alshahrani M; Gupta G; Verkhivker G
    Viruses; 2024 Sep; 16(9):. PubMed ID: 39339934
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Neutralization of SARS-CoV-2 BA.2.86 and JN.1 by CF501 adjuvant-enhanced immune responses targeting the conserved epitopes in ancestral RBD.
    Liu Z; Zhou J; Wang W; Zhang G; Xing L; Zhang K; Wang Y; Xu W; Wang Q; Man Q; Wang Q; Ying T; Zhu Y; Jiang S; Lu L
    Cell Rep Med; 2024 Mar; 5(3):101445. PubMed ID: 38428429
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024.
    Huiberts AJ; Hoeve CE; de Gier B; Cremer J; van der Veer B; de Melker HE; van de Wijgert JH; van den Hof S; Eggink D; Knol MJ
    Euro Surveill; 2024 Mar; 29(10):. PubMed ID: 38456217
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A Quick Displacement of the SARS-CoV-2 variant Delta with Omicron: Unprecedented Spike in COVID-19 Cases Associated with Fewer Admissions and Comparable Upper Respiratory Viral Loads.
    Fall A; Eldesouki RE; Sachithanandham J; Morris CP; Norton JM; Gaston DC; Forman M; Abdullah O; Gallagher N; Li M; Swanson NJ; Pekosz A; Klein EY; Mostafa HH
    medRxiv; 2022 Jan; ():. PubMed ID: 35118480
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Low SARS-CoV-2 viral load among vaccinated individuals infected with Delta B.1.617.2 and Omicron BA.1.1.529 but not with Omicron BA.1.1 and BA.2 variants.
    Selvavinayagam ST; Yong YK; Joseph N; Hemashree K; Tan HY; Zhang Y; Rajeshkumar M; Kumaresan A; Kalpana R; Kalaivani V; Monika AVD; Suvaithenamudhan S; Kannan M; Murugesan A; Narayanasamy K; Palani S; Larsson M; Shankar EM; Raju S
    Front Public Health; 2022; 10():1018399. PubMed ID: 36211690
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1.
    Hu Y; Zou J; Kurhade C; Deng X; Chang HC; Kim DK; Shi PY; Ren P; Xie X
    Emerg Microbes Infect; 2023 Dec; 12(2):2271089. PubMed ID: 37824708
    [TBL] [Abstract][Full Text] [Related]  

  • 67. SARS-CoV-2 Omicron variants: burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines.
    Pather S; Madhi SA; Cowling BJ; Moss P; Kamil JP; Ciesek S; Muik A; Türeci Ö
    Front Immunol; 2023; 14():1130539. PubMed ID: 37287979
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level.
    Akerman A; Milogiannakis V; Jean T; Esneau C; Silva MR; Ison T; Fichter C; Lopez JA; Chandra D; Naing Z; Caguicla J; Li D; Walker G; Amatayakul-Chantler S; Roth N; Manni S; Hauser T; Barnes T; Condylios A; Yeang M; Wong M; Foster CSP; Sato K; Lee S; Song Y; Mao L; Sigmund A; Phu A; Vande More AM; Hunt S; Douglas M; Caterson I; Britton W; Sandgren K; Bull R; Lloyd A; Triccas J; Tangye S; Bartlett NW; Darley D; Matthews G; Stark DJ; Petoumenos K; Rawlinson WD; Murrell B; Brilot F; Cunningham AL; Kelleher AD; Aggarwal A; Turville SG
    EBioMedicine; 2023 Apr; 90():104545. PubMed ID: 37002990
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa.
    Davies MA; Morden E; Rosseau P; Arendse J; Bam JL; Boloko L; Cloete K; Cohen C; Chetty N; Dane P; Heekes A; Hsiao NY; Hunter M; Hussey H; Jacobs T; Jassat W; Kariem S; Kassanjee R; Laenen I; Le Roux S; Lessells R; Mahomed H; Maughan D; Meintjes G; Mendelson M; Mnguni A; Moodley M; Murie K; Naude J; Ntusi NAB; Paleker M; Parker A; Pienaar D; Preiser W; Prozesky H; Raubenheimer P; Rossouw L; Schrueder N; Smith B; Smith M; Solomon W; Symons G; Taljaard J; Wasserman S; Wilkinson RJ; Wolmarans M; Wolter N; Boulle A
    medRxiv; 2022 Jul; ():. PubMed ID: 35794899
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters.
    Soudani N; Bricker TL; Darling T; Seehra K; Patel N; Guebre-Xabier M; Smith G; Davis-Gardner M; Suthar MS; Ellebedy AH; Boon ACM
    J Virol; 2024 Oct; 98(10):e0052824. PubMed ID: 39230305
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Outcomes of laboratory-confirmed SARS-CoV-2 infection during resurgence driven by Omicron lineages BA.4 and BA.5 compared with previous waves in the Western Cape Province, South Africa.
    Davies MA; Morden E; Rousseau P; Arendse J; Bam JL; Boloko L; Cloete K; Cohen C; Chetty N; Dane P; Heekes A; Hsiao NY; Hunter M; Hussey H; Jacobs T; Jassat W; Kariem S; Kassanjee R; Laenen I; Roux SL; Lessells R; Mahomed H; Maughan D; Meintjes G; Mendelson M; Mnguni A; Moodley M; Murie K; Naude J; Ntusi NAB; Paleker M; Parker A; Pienaar D; Preiser W; Prozesky H; Raubenheimer P; Rossouw L; Schrueder N; Smith B; Smith M; Solomon W; Symons G; Taljaard J; Wasserman S; Wilkinson RJ; Wolmarans M; Wolter N; Boulle A
    Int J Infect Dis; 2023 Feb; 127():63-68. PubMed ID: 36436752
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Editorial: The XBB.1.5 ('Kraken') Subvariant of Omicron SARS-CoV-2 and its Rapid Global Spread.
    Parums DV
    Med Sci Monit; 2023 Feb; 29():e939580. PubMed ID: 36722047
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Immune Evasion of SARS-CoV-2 Omicron Subvariants XBB.1.5, XBB.1.16 and EG.5.1 in a Cohort of Older Adults after ChAdOx1-S Vaccination and BA.4/5 Bivalent Booster.
    Machado RRG; Candido ÉD; Aguiar AS; Chalup VN; Sanches PR; Dorlass EG; Amgarten DE; Pinho JRR; Durigon EL; Oliveira DBL
    Vaccines (Basel); 2024 Jan; 12(2):. PubMed ID: 38400128
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Reinfection rate and disease severity of the BA.5 Omicron SARS-CoV-2 lineage compared to previously circulating variants of concern in the Canary Islands (Spain).
    Ciuffreda L; Lorenzo-Salazar JM; García-Martínez de Artola D; Gil-Campesino H; Alcoba-Florez J; Rodríguez-Pérez H; Íñigo-Campos A; Salas-Hernández J; Rodríguez-Nuñez J; Muñoz-Barrera A; Valenzuela-Fernández A; Díez-Gil O; González-Montelongo R; Flores C
    Emerg Microbes Infect; 2023 Dec; 12(1):2202281. PubMed ID: 37039029
    [No Abstract]   [Full Text] [Related]  

  • 75. Sera from breakthrough infections with SARS-CoV-2 BA.5 or BF.7 showed lower neutralization activity against XBB.1.5 and CH.1.1.
    Liu S; Liang Z; Nie J; Gao WB; Li X; Zhang L; Yu Y; Wang Y; Huang W
    Emerg Microbes Infect; 2023 Dec; 12(2):2225638. PubMed ID: 37313604
    [TBL] [Abstract][Full Text] [Related]  

  • 76. SARS-CoV-2 BA.1 and BA.2 breakthrough infections boost antibody responses to early Omicron subvariants but not BQ.1.1 or XBB.1.5.
    Abbad A; Yellin T; Singh G; Fried M; Raskin A; Tcheou J; Monahan B; Gleason C; ; Simon V; Carreño JM; Krammer F
    Cell Rep Med; 2024 Mar; 5(3):101474. PubMed ID: 38508136
    [TBL] [Abstract][Full Text] [Related]  

  • 77. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
    J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Estimation of disease burden and clinical severity of COVID-19 caused by Omicron BA.2 in Shanghai, February-June 2022.
    Chen X; Yan X; Sun K; Zheng N; Sun R; Zhou J; Deng X; Zhuang T; Cai J; Zhang J; Ajelli M; Yu H
    medRxiv; 2022 Jul; ():. PubMed ID: 35898339
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Evolving immune evasion and transmissibility of SARS-CoV-2: The emergence of JN.1 variant and its global impact.
    Ou G; Yang Y; Zhang S; Niu S; Cai Q; Liu Y; Lu H
    Drug Discov Ther; 2024 Mar; 18(1):67-70. PubMed ID: 38382991
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Antigenicity assessment of SARS-CoV-2 saltation variant BA.2.87.1.
    Yang S; Yu Y; Jian F; Yisimayi A; Song W; Liu J; Wang P; Xu Y; Wang J; Niu X; Yu L; Wang Y; Shao F; Jin R; Wang Y; Cao Y
    Emerg Microbes Infect; 2024 Dec; 13(1):2343909. PubMed ID: 38616729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.